10-Q: Hestia Insight Inc. Reports Strong Revenue Growth in Q2 2024, But Internal Control Weaknesses Persist

Hestia Insight Inc. reports a significant increase in revenue for the second quarter of 2024, but acknowledges ongoing issues with internal controls.

Summary

• Hestia Insight Inc. reported a substantial increase in revenue for the three and six months ended May 31, 2024, compared to the same periods in 2023.
• The company's revenue for the three months ended May 31, 2024, was $1,241,401, a significant jump from $30,000 in the same period of 2023.
• For the six months ended May 31, 2024, revenue reached $1,279,401, compared to $30,500 in the first half of 2023.
• The company's operating expenses decreased to $164,427 for the six months ended May 31, 2024, from $226,935 in the same period of 2023.
• Hestia Insight Inc. reported a net income of $1,148,597 for the six months ended May 31, 2024, a significant turnaround from a net loss of $287,116 in the same period of 2023.
• The company's cash balance decreased to $61,444 as of May 31, 2024, from $93,890 as of November 30, 2023.
• The company acknowledges that its disclosure controls and procedures were ineffective as of May 31, 2024, due to limited resources and a small number of employees.
• The company is dependent on debt and equity financing to fund its operations and has not yet established an ongoing source of revenues sufficient to cover its operating costs.

Sentiment

Score: 6

Explanation: The document shows a significant improvement in revenue and profitability, but the company's dependence on external funding and internal control weaknesses temper the overall positive sentiment. The company is in a high growth phase but with significant risks.

Positives

• The company experienced a significant increase in revenue, primarily from consulting services.
• Operating expenses decreased, contributing to improved profitability.
• Hestia Insight Inc. achieved a net income of $1,148,597 for the six months ended May 31, 2024, a significant turnaround from a net loss in the previous year.
• The company's investment in equities has increased substantially.

Negatives

• The company's cash balance decreased from $93,890 to $61,444.
• The company acknowledges that its disclosure controls and procedures were ineffective as of May 31, 2024.
• The company is dependent on debt and equity financing to fund its operations.
• The company has not yet established an ongoing source of revenues sufficient to cover its operating costs.

Risks

• The company's ability to continue as a going concern is dependent on its ability to generate revenue and obtain additional financing.
• The company's disclosure controls and procedures are currently ineffective, which could lead to inaccurate financial reporting.
• The company is subject to risks and uncertainties that could cause actual results to differ materially from forward-looking statements.
• The company's limited operating history and dependence on external funding pose significant risks.
• The company's reliance on a small number of employees and independent contractors could impact its ability to operate effectively.

Future Outlook

The company intends to pursue the acquisition and development of healthcare related technologies through acquisition, licensing, or joint ventures, and will also consider investing in certain technologies. The company will need to raise additional capital to fund its operations and growth.

Management Comments

• Management believes that it will be successful in its capital formation and planned operating activities.
• Management is making efforts to raise additional funding until a registration statement relating to an equity funding facility is in effect.
• Management concluded that the company's disclosure controls and procedures were ineffective as of May 31, 2024, due to limited resources and a small number of employees.

Industry Context

The company operates in the healthcare and biotech sectors, which are highly regulated and subject to rapid change. The company's focus on small and micro-cap companies with limited access to growth capital positions it within a specific niche of the market.

Comparison to Industry Standards

• The company's revenue growth is significant compared to its previous performance, but it is difficult to compare directly to industry standards without more specific information on comparable companies.
• The company's focus on consulting and strategic advisory services is common in the healthcare and biotech sectors, but the specific business model of targeting micro-cap companies is less common.
• The company's investment in equities is a unique aspect of its business model, and its performance will depend on the success of those investments.
• The company's internal control weaknesses are a concern and should be addressed to meet industry standards for public companies.

Related Party Transactions

• The company entered into a $50,000 note payable to ECL Capital Partners Corp, a related party, on January 15, 2024.
• An additional loan of $3,930.91 was received from Mr. Edward C. Lee as a short-term loan, bearing no interest.

Stakeholder Impact

• Shareholders will benefit from the improved financial performance, but face risks related to the company's dependence on external funding and internal control weaknesses.
• Employees may benefit from the company's growth, but face uncertainty related to the company's financial stability.
• Customers may benefit from the company's services, but face risks related to the company's financial stability.
• Creditors face risks related to the company's dependence on external funding and internal control weaknesses.

Next Steps

• The company will continue to pursue acquisitions and strategic partnerships in the healthcare and biotech sectors.
• The company will need to raise additional capital to fund its operations and growth.
• The company will need to address its internal control weaknesses to ensure accurate financial reporting.

Key Dates

Keywords

consulting, healthcare, biotech, revenue, financial results, investments, vending, internal controls, equity, operating expenses